Dr. Elaine S. Jaffe receives AMP's highest honor for pioneering contributions to lymphoma diagnosis and treatment. Dr. Laura J. Tafe is recognized for her leadership and service to the organization, while Dr. Daniel E. Sabath receives the Meritorious Service Award for his dedication to scientific excellence and organizational service.
Daniel E. Sabath, a professor at UW Department of Laboratory Medicine and Pathology, has won the Association for Molecular Pathology's 2026 Meritorious Service Award for his dedication and effort over three decades. He is being honored for his leadership roles, scientific expertise, and collaborative spirit in advancing education and s...
The Association for Molecular Pathology recognizes Dartmouth Health medical director Laura J. Tafe for her exceptional leadership and dedication to the field of molecular diagnostics. She has been a member of the organization since 2007 and has held various positions, including president in 2023.
Elaine S. Jaffe, a distinguished investigator at the NCI Center for Cancer Research, has transformed our understanding of lymphoid malignancies through her groundbreaking research. Her work has led to significant advancements in disease classifications, diagnosis, and treatment.
The Association for Molecular Pathology has elected new leaders for several committees, including Genetics, Hematopathology, Infectious Diseases, Informatics, and Solid Tumors. The newly elected leaders will work together to drive the organization's mission forward.
Scientists have developed a targeted genetic test to improve diagnosis for X-linked dystonia-parkinsonism, a rare and disabling movement disorder that affects primarily men of Filipino ancestry. The test correctly identified cases that routine sequencing methods have missed, leading to proper diagnoses and end diagnostic odysseys.
Researchers are presenting groundbreaking findings at the Association for Molecular Pathology's annual meeting, including a novel technique to study ancient DNA and rapid detection of serious fungal pathogens. The Association for Molecular Pathology is providing press materials and resources for media coverage.
Artificial intelligence is being used to improve diagnostic accuracy in molecular pathology, with studies showing 93% accuracy for cancer diagnosis. Researchers are also using AI to analyze chromosomal changes in blood cancer patients and provide personalized treatment plans.
Researchers have developed a new molecular test to identify Lyme disease earlier and more accurately than traditional methods. The test can detect as few as five bacterial cells and has an estimated sensitivity of 90.9%, making it a potential new avenue for testing Lyme disease.
Researchers have developed a molecular test capable of detecting three major pathogenic fungi at once, with a much quicker turnaround than traditional methods. The test bypasses the slow culture process by detecting genetic material directly, eliminating errors and reducing laboratory risk.
Researchers have discovered that optical genome mapping can reveal hidden causes of pregnancy loss, including chromosomal changes in genes known to be linked to recurrent pregnancy loss. The study found structural changes in the genome that were missed by traditional genetic sequencing methods.
Researchers have made significant advancements in diagnosing acute myeloid leukemia (AML), a common and aggressive form of blood cancer. Genetic testing can now predict relapse after stem cell transplant and detect hidden gene fusions that were previously undetectable.
Researchers developed a new DNA analysis technique to study old genetic samples, shedding light on disease evolution and changes in biology over time. The approach has potential for unlocking the root causes underlying shifting landscapes of modern diseases.
The Association for Molecular Pathology recognized Dr. Laposata's contributions to clinical laboratory practice and his role in challenging the FDA's rule on laboratory-developed test regulation. The award preserves diagnostic innovation, ensures patient access, and avoids escalating healthcare costs.
The Association for Molecular Pathology has created a standardized biomarker report template to simplify complex molecular profiling data presentation to oncologists and healthcare providers. The template includes guidelines for clear formatting, therapeutic guidance, and references to clinical practice guidelines.
Elaine R. Mardis, Alexis B. Carter, and Dara L. Aisner receive AMP's top honors for groundbreaking work in cancer genomics and molecular diagnostics. Drs. Mardis and Carter will deliver keynote lectures at the AMP Annual Meeting & Expo.
The Association for Molecular Pathology publishes guidelines for detecting homologous recombination deficiency (HRD) in cancer. The report includes recommendations for clinical laboratories, addressing technical aspects of genomic instability and HRD analysis.
The Association for Molecular Pathology (AMP) has announced the election results for 2026-2027 leadership positions, including President-Elect Yassmine M.N. Akkari and Secretary-Treasurer Jonathan A. Nowak. The newly elected leaders will drive AMP's mission to advance molecular diagnostics.
The Association for Molecular Pathology (AMP) has won a court ruling that vacates the FDA's rule on laboratory-developed test procedure regulation. This decision will avoid adding billions of dollars in healthcare costs and protect access to high-quality care for hundreds of millions of Americans.
The Association for Molecular Pathology has published a joint consensus report on SARS-CoV-2 genomic surveillance, outlining key considerations for next-generation sequencing methods. The report provides guidance on pre-analytical, analytical, and post-analytical aspects of NGS-based surveillance programs.
The Association for Molecular Pathology has published consensus guidelines for clinical DPYD genotyping assays to improve patient care and standardize testing. The recommendations include a tiered system of variants with well-characterized effects on protein function, gene expression, and minor allele frequency.
The Association for Molecular Pathology has published guidelines for tumor mutational burden (TMB) testing, aiming to standardize calculation and reporting of TMB as a predictive biomarker for immune checkpoint inhibitor therapies. These recommendations emphasize the importance of comprehensive methodological descriptions in publications.
The Association for Molecular Pathology published a report outlining considerations for a slice testing strategy, including gene selection and quality. This approach combines the advantages of high-quality gene panels with flexibility and broad scope of exome sequencing.
The Association for Molecular Pathology published guidelines for validating and reporting clinical circulating tumor DNA assays. The recommendations aim to promote standardization and quality improvement in liquid biopsy assays, which have emerged as a key technology in molecular diagnostics.
A joint consensus report by AMP, ASM, IDSA, and PASCV outlines the clinical and analytical benefits of multiplex PCR panels for detecting pathogens from various body sites. The report also discusses future directions and challenges associated with these panels.
The Association for Molecular Pathology has published clinical CYP3A4 and CYP3A5 genotyping assay recommendations to standardize testing across laboratories. The guidelines aim to improve patient care by providing guidance on allele selection, assay validation, and therapeutic recommendations.
The Association for Molecular Pathology (AMP) has published a report establishing evidence-based recommendations for orthogonal confirmation practices of germline variants detected by next-generation sequencing. The guidelines aim to promote standardization, transparency, and quality improvement among laboratories.
The Association for Molecular Pathology (AMP) published a report assessing the clinical adoption, classification inconsistencies, and implementation barriers of the 2017 guidelines for sequence variant interpretation and reporting in cancer. The study found that 86% of participants correctly differentiated clinically significant varian...
The Association for Molecular Pathology (AMP) has published consensus recommendations for using in silico approaches to validate Next-Generation Sequencing (NGS) data analysis pipelines. The guidelines provide expert opinion on the advantages and disadvantages of different types of in silico data and offer general recommendations for s...
The Association for Molecular Pathology has published consensus recommendations for clinical TPMT and NUDT15 genotyping assays, promoting standardization across laboratories. The report identifies a minimum set of alleles to include in clinical tests, enabling healthcare professionals to provide high-quality patient care.
Ronald M. Przygodzki, MD, has been appointed as the new Editor-in-Chief of The Journal of Molecular Diagnostics, succeeding Barbara Zehnbauer, PhD. Dr. Przygodzki brings extensive experience in genomic medicine and molecular diagnostics to the position.
The Association for Molecular Pathology (AMP) has published new guidelines to improve the US' ability to respond to emerging infectious disease outbreaks. The recommendations focus on better collaboration between public health, clinical laboratories, and government agencies.
The Association for Molecular Pathology (AMP) has published consensus recommendations for clinical CYP2D6 genotype testing, aiming to standardize testing across laboratories and improve patient care. A minimum set of variants is recommended for inclusion in all future clinical assays.
Drs. Dennis Lo, Karen Mann and Ronald Przygodzki are recognized for their pioneering work in non-invasive prenatal testing and cancer detection using circulating nucleic acids. Their innovations have created a paradigm in prenatal medicine and advanced the field of molecular diagnostics.
The Association for Molecular Pathology (AMP) has released consensus recommendations to aid in the design, validation and interpretation of clinical genotyping tests for predicting warfarin response. The guidelines define a minimum set of pharmacogenetic alleles for inclusion in clinical warfarin sensitivity genotyping tests.
A joint report from AMP and CAP provides evidence-based recommendations for designing and validating clinical CYP2C9 assays, promoting standardization and improving patient care. The report defines a minimum set of alleles and their variants that should be included in all clinical CYP2C9 genotyping tests.
Drs. Jonathan Rothberg, Roger Klein and Kevin Halling are being recognized for their groundbreaking work and longstanding commitment to advancing patient care and the field of molecular diagnostics. Drs. Rothberg is receiving AMP's highest honor for his pioneering work in genomics and inventions like massively parallel DNA sequencing.
The Association for Molecular Pathology recommends a minimum of 34 critical genes for high-throughput pan-myeloid sequencing tests to standardize clinical practice and improve patient care. The report provides evidence-based guidelines for the management of chronic myeloid neoplasms, including diagnostic and prognostic information.
The Association for Molecular Pathology (AMP) has published consensus-based recommendations for clinical CYP2C19 genotyping allele selection. The guidelines aim to standardize testing across laboratories and improve concordance, enabling better patient care.
The Association for Molecular Pathology publishes consensus recommendations for validating next-generation sequencing bioinformatics pipelines. The guidelines emphasize the critical role of trained molecular laboratory professionals and provide practical advice for laboratories.
The Association for Molecular Pathology (AMP) has awarded prestigious honors to Drs. Andrew P. Feinberg, Gregory J. Tsongalis, and Alexis B. Carter for their outstanding contributions to the field of molecular diagnostics. AMP President Federico A. Monzon praised the award recipients for their decades of service to the society.
The Association for Molecular Pathology published consensus recommendations to validate next-generation sequencing (NGS)-based oncology panels. The guidelines address NGS test development, optimization and familiarization, and best practices for establishing test performance characteristics.
The Association for Molecular Pathology (AMP) has published a joint guideline to standardize the interpretation and reporting of sequence variants in cancer. The guidelines aim to improve patient care by establishing standardized classification, annotation, interpretation, and reporting conventions for somatic sequence variants.
The Association for Molecular Pathology released a new report highlighting the potential of MALDI-TOF-MS in identifying invasive infectious diseases. The technology has been shown to accurately identify filamentous fungi and mycobacteria, but more testing is needed before its use can be recommended.
Eric Lander receives the award for his lifetime achievements in molecular diagnostics, transforming our understanding of rare and common genetic diseases. The AMP Award recognizes Dr. Lander's seminal publications, fundamental discoveries, and significant scientific contributions.
The Association for Molecular Pathology has developed a new framework for defining the clinical utility of molecular diagnostics, emphasizing the importance of context in interpreting test results. This approach aims to improve patient care by providing clinically useful and appropriate testing based on realistic evidence levels.
A new publication by the Association for Molecular Pathology provides cost and value analysis of gene panels, including non-small cell lung cancer and hearing loss. The study demonstrates economic value in optimizing care for patients with hereditary diseases and cancer through targeted gene panels.
The Association for Molecular Pathology (AMP) has updated its pathology residency curriculum recommendations, focusing on 10 major molecular pathology topics. The new report aims to equip pathologists with the latest scientific breakthroughs and technological innovations in molecular pathology.
The Association for Molecular Pathology compiles current research on liquid biopsy approaches for cancer diagnostics. The review supports the notion that these minimally invasive tests allow for earlier diagnosis, faster and more targeted treatment, reduced costs, and increased quality of life.
The Journal of Molecular Diagnostics published a Special Article on laboratory perspective of incidental findings reporting, highlighting the need for increased understanding and transparency of complex genomic testing. The AMP Incidental Findings Working Group recommends laboratories establish clear policies for delivering ancillary i...